West Pharmaceutical Services, Inc. announced strong fourth-quarter and full-year 2025 financial results. The company's fourth-quarter net sales increased by 7.5% to $805.0 million, with organic growth of 3.3%. Diluted EPS grew by 2.2% to $1.82, while Adjusted-diluted EPS increased by 12.1% to $2.04. The Proprietary Products Segment, particularly High-Value Product Components, was a key driver of this performance.

West Pharmaceutical Services reported strong Q3 2025 results with 5.0% organic sales growth and improved adjusted EPS. High-Value Product Components saw double-digit growth, and the company raised its full-year guidance on both revenue and EPS.

West Pharmaceutical Services delivered $766.5 million in net sales for Q2 2025, driven by strong growth in proprietary products, especially high-value components and delivery devices. Net income rose to $131.8 million, and adjusted EPS increased to $1.84. The company raised its full-year 2025 guidance on both revenue and adjusted EPS.

West delivered solid Q1 2025 results with net sales growth and higher-than-expected EPS, supported by strength in self-injection device platforms and improved free cash flow.

West Pharmaceutical Services reported a 2.3% increase in revenue for Q4 2024, driven by strong demand for high-value self-injection devices. However, EPS declined slightly due to higher costs and currency headwinds.

West Pharmaceutical Services reported a slight decrease in net sales for Q3 2024, with a marginal decline in organic net sales. Despite this, the company increased its full-year net sales and adjusted EPS guidance, citing favorable currency movements. The Board of Directors also approved a fourth-quarter dividend increase.

West Pharmaceutical Services reported a 6.9% decrease in net sales to $702.1 million and a decline in diluted EPS to $1.51 for Q2 2024. The company is updating its full-year net sales guidance to $2.870 billion to $2.900 billion and adjusted-diluted EPS guidance to $6.35 to $6.65 due to the impact of customer destocking.

West Pharmaceutical Services reported a 3.0% decrease in net sales to $695.4 million and a 16.2% decline in reported diluted EPS to $1.55 for the first quarter of 2024. The company reaffirmed its full-year net sales guidance of $3.000 billion to $3.025 billion and raised its full-year adjusted diluted EPS guidance to a new range of $7.63 to $7.88.

West Pharmaceutical Services, Inc. announced its Q4 and full-year 2023 financial results, with Q4 net sales reaching $732.0 million, a 3.3% increase, and adjusted-diluted EPS of $1.83, a 3.4% increase. The company introduced full-year 2024 financial guidance, expecting net sales between $3.000 billion and $3.025 billion and adjusted-diluted EPS between $7.50 and $7.75.

West Pharmaceutical Services reported net sales of $747.4 million, an 8.8% increase, with organic net sales growth of 5.7%. Reported diluted EPS increased by 34.6% to $2.14, while adjusted diluted EPS rose by 6.4% to $2.16. The company updated its full-year net sales guidance to $2.950 billion to $2.960 billion and adjusted diluted EPS guidance to $7.95 to $8.00.

West Pharmaceutical Services reported a decrease in net sales by 2.3% and a decline in reported-diluted EPS from $2.48 to $2.06 compared to the same period last year. However, the company is raising its full-year net sales and adjusted-diluted EPS guidance, reflecting confidence in its high-value product capacity expansion projects.

West Pharmaceutical Services reported a slight decrease in net sales by 0.5% to $716.6 million, but organic sales grew by 2.3%. Reported-diluted EPS decreased by 19.2% to $1.85, and adjusted-diluted EPS declined by 13.9% to $1.98. The company updated its full-year 2023 financial guidance for net sales to a range of $2.965 billion to $2.990 billion and adjusted-diluted EPS to a range of $7.50 to $7.65.

West Pharmaceutical Services reported a decrease in net sales and EPS for Q4 2022 compared to the prior-year period. Net sales decreased by 3.0% to $708.7 million, and reported-diluted EPS decreased by 29.5% to $1.36. The company is introducing full-year 2023 financial guidance of net sales in a range of $2.935 billion to $2.960 billion and adjusted-diluted EPS in a range of $7.25 to $7.40.

West Pharmaceutical Services reported a decrease in net sales by 2.8% to $686.9 million, with organic net sales growth of 4.3%. Reported-diluted EPS decreased by 31.2% to $1.59, and adjusted-diluted EPS declined by 1.5% to $2.03. The company updated its full-year net sales guidance to $2.830 billion to $2.840 billion and adjusted-diluted EPS guidance to $8.15 to $8.20.

West Pharmaceutical Services announced its financial results for the second quarter of 2022, reporting net sales of $771.3 million, a 6.6% increase compared to the prior-year period. Organic net sales growth was 13.1%. The company updated its full-year 2022 net sales guidance to a range of $2.950 billion to $2.975 billion and adjusted-diluted EPS guidance to a new range of $9.00 to $9.15.

West Pharmaceutical Services reported a strong first quarter in 2022, with net sales reaching $720.0 million, a 7.4% increase compared to the prior-year period. The company reaffirmed its full-year 2022 net sales guidance and raised its adjusted-diluted EPS guidance.

West Pharmaceutical Services reported a successful 2021 with record organic sales growth and gross operating margin expansion. Fourth-quarter net sales grew by 26.0% to $730.8 million, with organic sales growth of 28.3%. Reported-diluted EPS increased 49.6% to $1.93, and adjusted-diluted EPS increased 52.2% to $2.04.

West Pharmaceutical Services, Inc. reported a strong third quarter in 2021, with net sales increasing by 28.9% to $706.5 million and adjusted-diluted EPS increasing by 79% to $2.06. The company is raising full-year 2021 net sales and adjusted-diluted EPS guidance.

West Pharmaceutical Services reported a strong second quarter with net sales of $723.6 million, a 37.3% increase, and diluted EPS of $2.47, a 104% increase. The company is raising its full-year 2021 net sales and adjusted-diluted EPS guidance.

West Pharmaceutical Services, Inc. announced strong first-quarter 2021 results, with net sales reaching $670.7 million, a 36.5% increase. Diluted EPS increased by 101% to $1.99, and adjusted-diluted EPS rose by 103% to $2.05. The company raised its full-year 2021 net sales and adjusted-diluted EPS guidance.

West Pharmaceutical Services, Inc. reported a strong fourth quarter and full year 2020, with record full-year net sales, organic sales growth, and operating profit margin. The fourth quarter saw robust results, led by growth in Biologics and Generics market units, and an acceleration in COVID-19-associated sales of high-value product components.

West Pharmaceutical Services reported strong third-quarter results with net sales growing by 20.1% and adjusted-diluted EPS increasing by 46%. The company raised its full-year 2020 net sales and adjusted-diluted EPS guidance.

West Pharmaceutical Services reported a 12.2% increase in net sales to $527.2 million and a 40% increase in adjusted-diluted EPS to $1.25 for the second quarter of 2020. The company is raising full-year 2020 net sales guidance to between $2.035 billion and $2.055 billion, and adjusted-diluted EPS guidance to between $4.15 and $4.25.

West Pharmaceutical Services announced its financial results for the first-quarter 2020. Net sales of $491.5 million grew 10.8%; organic sales growth was 12.7%. Reported-diluted EPS of $0.99 increased 36%. Adjusted-diluted EPS of $1.01 increased 36%. The Company is maintaining full-year 2020 net sales guidance and is updating full-year 2020 adjusted-diluted EPS guidance to a new range of $3.52 to $3.62, compared to a prior range of $3.45 to $3.55.

West Pharmaceutical Services, Inc. announced its financial results for the fourth-quarter and full-year 2019. Fourth-quarter 2019 net sales of $470.6 million grew 11.4%, reported-diluted EPS of $0.84 increased 22%, and adjusted-diluted EPS of $0.82 increased 12%.